Market Cap 2.51M
Revenue (ttm) 90,000.00
Net Income (ttm) -13.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -15,511.11%
Debt to Equity Ratio -0.10
Volume 698,528
Avg Vol 4,380,106
Day's Range N/A - N/A
Shares Out 8.15M
Stochastic %K 5%
Beta 1.24
Analysts Sell
Price Target $14.00

Company Profile

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon produ...

Industry: Biotechnology
Sector: Healthcare
Phone: 352 448 7797
Fax: 352 480 4620
Address:
2117 SW Highway 484, Ocala, United States
Andrebrx1
Andrebrx1 May. 13 at 10:09 PM
$AIM no escape from RS but i doubt they will be delisted. Dont they have a data redout for Duripanc next month? That can serve as a catalyst . The only question is will it be before or after the RS😂
1 · Reply
ultimatebastos
ultimatebastos May. 13 at 7:16 PM
$AIM https://orcacapital.de/en/about/
0 · Reply
ultimatebastos
ultimatebastos May. 13 at 5:11 PM
$AIM how is the new 10% owner hedge related to Kellner?
1 · Reply
jonjonson1234
jonjonson1234 May. 13 at 2:46 PM
$AIM It appears that the company's diligent efforts to dilute itself into oblivion are continuing to drive down the share price. The 10-Q should come out Friday and will give an update on how many shares outstanding they are up to. Remember, a year ago, just after the 1-for-100 reverse split, they were down to less than 750,000 shares outstanding. The amount that they have managed to dilute themselves since then has been nothing short of amazing. In the 10-K they reported that they were up to 8,147,782. Since then it appears that they have diluted themselves by roughly another 8 million shares. If they really are up to 16+million shares outstanding, that would mean that all of the retail share from prior to the reverse split constitute only 4.6% of the current total. Or, you could say that they have diluted themselves by 2133% in the past year. Another key number to watch in the 10-Q will be shareholder's equity.
2 · Reply
M2023
M2023 May. 13 at 2:09 PM
$AIM is it stuck?
0 · Reply
EarningsInsider
EarningsInsider May. 13 at 1:15 PM
https://www.marketbeat.com/earnings/reports/2026-5-13-aimia-inc-aimto-stock/ $AIM Aimia Earnings Transcript
1 · Reply
sschmid1
sschmid1 May. 13 at 9:30 AM
$AIM https://s3.amazonaws.com/sec.irpass.cc/2265/0001493152-26-022501.htm The Orca 13G gives us two important insights 👇 1. Real share count * 1.79M = 9.9% 👉 implies ~18M shares outstanding That allows you to reconcile: * warrant exercises * inducement * prior raises 👉 ~$9M+ cash raised since year-end ⸻ 2. Position build may NOT be from inducement Orca files 13Gs even for small positions (not just >5%), which suggests: 👉 they could have accumulated a large part of the 1.79M in the open market Given: * ~8.6M volume on May 7 * timing of the filing 👉 not necessarily purely a discounted inducement play ⸻ Bottom line: At least one institutional player may have been actively buying into liquidity, not just taking structured dilution.
1 · Reply
focafoca99
focafoca99 May. 12 at 10:29 PM
$AIM closed a $3.6 million warrant exercise inducement, issuing new Class H warrants and paying placement fees. https://www.rapidticker.com/news/aim-sec-filing-cfafde
0 · Reply
Teleboy
Teleboy May. 12 at 8:37 PM
$AIM Two new SEC Filings just posted. Linked below.
0 · Reply
Teleboy
Teleboy May. 12 at 8:37 PM
$AIM https://s3.amazonaws.com/sec.irpass.cc/2265/0001493152-26-022501.htm
1 · Reply
Latest News on AIM
AIM ImmunoTech Transcript: Virtual Investor Closing Bell

Apr 16, 2026, 4:00 PM EDT - 27 days ago

AIM ImmunoTech Transcript: Virtual Investor Closing Bell


AIM ImmunoTech Provides Routine Update on Annual Filings

Apr 13, 2026, 6:00 PM EDT - 4 weeks ago

AIM ImmunoTech Provides Routine Update on Annual Filings


Biotech Alert: Searches spiking for these stocks today

2026-03-20T14:55:28.000Z - 7 weeks ago

Biotech Alert: Searches spiking for these stocks today


Why Is AIM ImmunoTech Stock (AIM) Up Today?

2026-03-18T13:47:09.000Z - 2 months ago

Why Is AIM ImmunoTech Stock (AIM) Up Today?


AIM announces approval of patent for Ampligen in Japan

2026-03-18T12:51:46.000Z - 2 months ago

AIM announces approval of patent for Ampligen in Japan


AIM ImmunoTech Announces Closing of its Rights Offering

Mar 6, 2026, 7:00 PM EST - 2 months ago

AIM ImmunoTech Announces Closing of its Rights Offering


Biotech Alert: Searches spiking for these stocks today

2026-03-04T15:25:35.000Z - 2 months ago

Biotech Alert: Searches spiking for these stocks today


AIM ImmunoTech announces preliminary results of rights offering

2026-03-04T14:05:33.000Z - 2 months ago

AIM ImmunoTech announces preliminary results of rights offering


AIM ImmunoTech extends subscription period of rights offering

2026-02-25T14:19:06.000Z - 2 months ago

AIM ImmunoTech extends subscription period of rights offering


AIM ImmunoTech Transcript: Virtual Investor Closing Bell

Feb 19, 2026, 4:00 PM EST - 2 months ago

AIM ImmunoTech Transcript: Virtual Investor Closing Bell


AIM ImmunoTech Transcript: Corporate Connect Webinar Series

Feb 11, 2026, 1:40 PM EST - 3 months ago

AIM ImmunoTech Transcript: Corporate Connect Webinar Series


AIM ImmunoTech announces commencement of rights offering

2026-02-11T13:35:13.000Z - 3 months ago

AIM ImmunoTech announces commencement of rights offering


AIM ImmunoTech Announces Commencement of Rights Offering

Feb 11, 2026, 8:30 AM EST - 3 months ago

AIM ImmunoTech Announces Commencement of Rights Offering


Biotech Alert: Searches spiking for these stocks today

2026-02-09T16:55:26.000Z - 3 months ago

Biotech Alert: Searches spiking for these stocks today


Biotech Alert: Searches spiking for these stocks today

2026-02-06T16:45:33.000Z - 3 months ago

Biotech Alert: Searches spiking for these stocks today


Why Is AIM ImmunoTech Stock Up Today?

2026-02-05T14:18:08.000Z - 3 months ago

Why Is AIM ImmunoTech Stock Up Today?


AIM ImmunoTech Inc trading resumes

2026-01-23T18:40:14.000Z - 3 months ago

AIM ImmunoTech Inc trading resumes


AIM ImmunoTech Inc trading halted, news pending

2026-01-23T17:30:16.000Z - 3 months ago

AIM ImmunoTech Inc trading halted, news pending


AIM ImmunoTech Transcript: AGM 2025

Dec 16, 2025, 11:00 AM EST - 5 months ago

AIM ImmunoTech Transcript: AGM 2025


AIM ImmunoTech Transcript: Virtual Investor Closing Bell Series

Dec 4, 2025, 4:00 PM EST - 5 months ago

AIM ImmunoTech Transcript: Virtual Investor Closing Bell Series


AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

Oct 20, 2025, 9:15 AM EDT - 7 months ago

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit


AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Aug 21, 2025, 9:00 AM EDT - 9 months ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment


AIM ImmunoTech Resumes Trading on NYSE American

Jun 17, 2025, 8:55 AM EDT - 11 months ago

AIM ImmunoTech Resumes Trading on NYSE American


AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

Jun 11, 2025, 4:15 PM EDT - 1 year ago

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split


AIM ImmunoTech Earnings Call Transcript: Q4 2024

Apr 1, 2025, 8:30 AM EDT - 1 year ago

AIM ImmunoTech Earnings Call Transcript: Q4 2024


Andrebrx1
Andrebrx1 May. 13 at 10:09 PM
$AIM no escape from RS but i doubt they will be delisted. Dont they have a data redout for Duripanc next month? That can serve as a catalyst . The only question is will it be before or after the RS😂
1 · Reply
ultimatebastos
ultimatebastos May. 13 at 7:16 PM
$AIM https://orcacapital.de/en/about/
0 · Reply
ultimatebastos
ultimatebastos May. 13 at 5:11 PM
$AIM how is the new 10% owner hedge related to Kellner?
1 · Reply
jonjonson1234
jonjonson1234 May. 13 at 2:46 PM
$AIM It appears that the company's diligent efforts to dilute itself into oblivion are continuing to drive down the share price. The 10-Q should come out Friday and will give an update on how many shares outstanding they are up to. Remember, a year ago, just after the 1-for-100 reverse split, they were down to less than 750,000 shares outstanding. The amount that they have managed to dilute themselves since then has been nothing short of amazing. In the 10-K they reported that they were up to 8,147,782. Since then it appears that they have diluted themselves by roughly another 8 million shares. If they really are up to 16+million shares outstanding, that would mean that all of the retail share from prior to the reverse split constitute only 4.6% of the current total. Or, you could say that they have diluted themselves by 2133% in the past year. Another key number to watch in the 10-Q will be shareholder's equity.
2 · Reply
M2023
M2023 May. 13 at 2:09 PM
$AIM is it stuck?
0 · Reply
EarningsInsider
EarningsInsider May. 13 at 1:15 PM
https://www.marketbeat.com/earnings/reports/2026-5-13-aimia-inc-aimto-stock/ $AIM Aimia Earnings Transcript
1 · Reply
sschmid1
sschmid1 May. 13 at 9:30 AM
$AIM https://s3.amazonaws.com/sec.irpass.cc/2265/0001493152-26-022501.htm The Orca 13G gives us two important insights 👇 1. Real share count * 1.79M = 9.9% 👉 implies ~18M shares outstanding That allows you to reconcile: * warrant exercises * inducement * prior raises 👉 ~$9M+ cash raised since year-end ⸻ 2. Position build may NOT be from inducement Orca files 13Gs even for small positions (not just >5%), which suggests: 👉 they could have accumulated a large part of the 1.79M in the open market Given: * ~8.6M volume on May 7 * timing of the filing 👉 not necessarily purely a discounted inducement play ⸻ Bottom line: At least one institutional player may have been actively buying into liquidity, not just taking structured dilution.
1 · Reply
focafoca99
focafoca99 May. 12 at 10:29 PM
$AIM closed a $3.6 million warrant exercise inducement, issuing new Class H warrants and paying placement fees. https://www.rapidticker.com/news/aim-sec-filing-cfafde
0 · Reply
Teleboy
Teleboy May. 12 at 8:37 PM
$AIM Two new SEC Filings just posted. Linked below.
0 · Reply
Teleboy
Teleboy May. 12 at 8:37 PM
$AIM https://s3.amazonaws.com/sec.irpass.cc/2265/0001493152-26-022501.htm
1 · Reply
Teleboy
Teleboy May. 12 at 8:37 PM
$AIM https://s3.amazonaws.com/sec.irpass.cc/2265/0001493152-26-022499.htm
0 · Reply
Chessdoc
Chessdoc May. 12 at 7:43 PM
$AIM Delisting would suck, however, the way to value the company remains in its future potential. If we continue to witness clinical success, the value of Ampligen is valued in billions of dollars. Not a bad risk return for a market cap of under 3 million. NFA, however, my strategy is own some shares now, be ready to double or triple down if de listing ensues. Curious how others are approaching this challenging time?
2 · Reply
Andrebrx1
Andrebrx1 May. 12 at 5:36 PM
$AIM its a very high risk gamble at this point . If it doesn't delist next month and no RS chances are it goes 100% + . Chances are low of course
2 · Reply
Cheffinance
Cheffinance May. 12 at 4:00 PM
$AIM this are not shorts, but only managers with their crazy politics of diluition that use retails despite private equity.
1 · Reply
ultimatebastos
ultimatebastos May. 12 at 3:27 PM
$AIM naked shorts we see here make people stop investing all together. They are pure bread criminals. Ampligen is real and it would be a big loss for the world if the criminals get what they want
1 · Reply
Cheffinance
Cheffinance May. 12 at 2:10 PM
$AIM the end, save what you can save e run away as soon as possible!
0 · Reply
Chessdoc
Chessdoc May. 12 at 1:06 PM
$AIM Same argument could be made for us – – although they would acquire us for a mere pittance comparatively. https://stocktwits.com/Duncan74/message/653055682
0 · Reply
Teleboy
Teleboy May. 12 at 12:35 PM
$AIM Rintatolimod referenced in Pancreatic cancer review article. This "summarizes recent progress in PDAC immunotherapy, highlights key challenges, and discusses emerging approaches designed to improve patient outcomes." This covers promising studies in the field. https://pmc.ncbi.nlm.nih.gov/articles/PMC13139486/
0 · Reply
sschmid1
sschmid1 May. 12 at 5:17 AM
$AIM Something doesn’t fully add up in the latest warrant inducement from last Friday. The official PR and 8-K focus on Class A–F, but the inducement letter appears to include Class G warrants as well. 👉 If that’s the case: were Class G holders included or excluded in practice? Would be helpful if anyone holding G warrants could share whether they were contacted.
1 · Reply
PhantaJuicy
PhantaJuicy May. 11 at 9:00 PM
$AIM The deadline for SEC compliance is June 11. The two main issues are minimum stock price and required shareholder equity. A quick AI search showed this: (1) To regain compliance with the price requirement, the stock must maintain a closing bid price of at least $1 for a minimum of 10 consecutive business days. Deadline for Compliance: June 11, 2026. This means the price has to be at least $1, starting June 1, for compliance. In addition, stockholder equity must be at least $6 million. Equels has not maintained that minimum threshold. New "Immediate Delisting" Threshold: A proposed rule change filed in late 2025 states that a company may be subject to immediate suspension and delisting if its average global market capitalization falls below $5 million over a consecutive 30-day period. Equels has not maintained that minimum threshold.
3 · Reply
DrInvest26
DrInvest26 May. 11 at 6:37 PM
$AIM Anyone knows if earnings anytime soon?
1 · Reply
M2023
M2023 May. 11 at 4:57 PM
$AIM this thing should rocket soon
2 · Reply